Anti-galectin 3 antibodies and their use in epilepsy and related diseases

An antibody or a binding fragment thereof that binds to Galectin-3, wherein the antibody comprises:

• a heavy chain variable (VH) region comprising
• a HCDR1 amino acid sequence of SEQ ID NO:
• 4, a HCDR2 amino acid sequence of SEQ ID NO:
• 25, and a HCDR3 amino acid sequence of SEQ ID NO:
• 46, and
• a light chain variable (VL) region comprising
• a LCDR1 amino acid sequence of SEQ ID NO:
• 172, a LCDR2 amino acid sequence of SEQ ID NO:
• 193, and a LCDR3 amino acid sequence of SEQ ID NO:
• 214;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 373, a HCDR2 amino acid sequence of SEQ ID NO:
• 393, and a HCDR3 amino acid sequence of SEQ ID NO:
• 419, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 447, a LCDR2 amino acid sequence of SEQ ID NO:
• 470, and a LCDR3 amino acid sequence of SEQ ID NO:
• 484;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 370, a HCDR2 amino acid sequence of SEQ ID NO:
• 390, and a HCDR3 amino acid sequence of SEQ ID NO:
• 418, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 440, a LCDR2 amino acid sequence of SEQ ID NO:
• 463, and a LCDR3 amino acid sequence of SEQ ID NO:
• 481;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 386, a HCDR2 amino acid sequence of SEQ ID NO:
• 412, and a HCDR3 amino acid sequence of SEQ ID NO:
• 434, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 460, a LCDR2 amino acid sequence of SEQ ID NO:
• 479, and a LCDR3 amino acid sequence of SEQ ID NO:
• 502;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 2, a HCDR2 amino acid sequence of SEQ ID NO:
• 23, and a HCDR3 amino acid sequence of SEQ ID NO:
• 44, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 170, a LCDR2 amino acid sequence of SEQ ID NO:
• 191, and a LCDR3 amino acid sequence of SEQ ID NO:
• 212;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 374, a HCDR2 amino acid sequence of SEQ ID NO:
• 394, and a HCDR3 amino acid sequence of SEQ ID NO:
• 420, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 444, a LCDR2 amino acid sequence of SEQ ID NO:
• 467, and a LCDR3 amino acid sequence of SEQ ID NO:
• 485;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 376, a HCDR2 amino acid sequence of SEQ ID NO:
• 396, and a HCDR3 amino acid sequence of SEQ ID NO:
• 422, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 446, a LCDR2 amino acid sequence of SEQ ID NO:
• 469, and a LCDR3 amino acid sequence of SEQ ID NO:
• 487;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 5, a HCDR2 amino acid sequence of SEQ ID NO:
• 26, and a HCDR3 amino acid sequence of SEQ ID NO:
• 47, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 173, a LCDR2 amino acid sequence of SEQ ID NO:
• 194, and a LCDR3 amino acid sequence of SEQ ID NO:
• 215;
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 3, a HCDR2 amino acid sequence of SEQ ID NO:
• 24, and a HCDR3 amino acid sequence of SEQ ID NO:
• 45, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 171, a LCDR2 amino acid sequence of SEQ ID NO:
• 192, and a LCDR3 amino acid sequence of SEQ ID NO:
• 213;
• or
• a VH region comprising a HCDR1 amino acid sequence of SEQ ID NO:
• 375, a HCDR2 amino acid sequence of SEQ ID NO:
• 395, and a HCDR3 amino acid sequence of SEQ ID NO:
• 421, and a VL region comprising a LCDR1 amino acid sequence of SEQ ID NO:
• 445, a LCDR2 amino acid sequence of SEQ ID NO:
• 468, and a LCDR3 amino acid sequence of SEQ ID NO:
• 486.